Alzheimer’s Treatment Needs More Than Amyloid Drugs
Alzheimer’s Treatment Needs More Than Amyloid TL;DR: A 2026 review in Science China Life Sciences argues that amyloid-beta antibodies such as lecanemab and donanemab are important progress, but Alzheimer’s treatment cannot stop at amyloid. The disease also involves tau tangles, genetics, aging biology, immune changes, vascular and metabolic health, and systemic conditions that shape whether …
